• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,783.53 870.03
( 1.13%)
Global Indices
Nasdaq
49,530.46 -142.69
(-0.29%)
Dow Jones
7,252.74 22.73
(0.31%)
Hang Seng
59,594.47 309.55
(0.52%)
Nikkei 225
10,375.34 -3.48
(-0.03%)
Forex
USD-INR
94.96 0.17
(0.17%)
EUR-INR
111.11 0.25
(0.23%)
GBP-INR
128.48 0.55
(0.43%)
JPY-INR
0.60 0.01
(1.28%)

EQUITY - MARKET SCREENER

A G Universal Ltd
Industry :  Aluminium and Aluminium Products
BSE Code
ISIN Demat
Book Value()
78456
INE0O6N01012
34.242159
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AGUL
34.45
31.18
EPS(TTM)
Face Value()
Div & Yield %
1.65
10
0
 

astec lifesciences ltd
Aarti Pharmalabs slides after Q2 PAT tumbles 49% YoY to Rs 28 cr
Nov 10,2025
Revenue from operations fell 8.66% YoY to Rs 418.33 crore in the quarter ended 30 September 2025.

Profit before tax (PBT) stood at Rs 38.69 crore in Q2 FY26, down 46.09% from Rs 71.77 crore in the same period last year.

Total expenses decreased 2.99% to Rs 379.05 crore in Q2 FY26, compared to Rs 379.05 crore in Q2 FY26. The cost of materials consumed stood at Rs 203.46 crore (down 4.91% YoY), employee benefit expenses were Rs 43.41 crore (up 15.05% YoY) and finance costs stood at Rs 10.67 crore (up 93.64% YoY) during the period under review.

On half-year basis, the company's consolidated net profit climbed 29.64% to Rs 77.45 crore on 20.62% decrease in revenue to Rs 804.53 crore in H1 FY26 over H1 FY25.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.